Axon Enterprise (NASDAQ:AXON) Given New $700.00 Price Target at The Goldman Sachs Group

Axon Enterprise (NASDAQ:AXON) had its target price boosted by The Goldman Sachs Group from $500.00 to $700.00 in a research note published on Monday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the stock. Needham & Company LLC boosted their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a report on Friday, November 8th. Robert W. Baird raised their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. JMP Securities upped their price target on shares of Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 31st. TD Cowen started coverage on Axon Enterprise in a research note on Wednesday, January 8th. They issued a “buy” rating and a $700.00 target price on the stock. Finally, Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $500.00 to $700.00 in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $524.85.

Axon Enterprise Trading Up 0.4 %

Shares of AXON opened at $639.97 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise has a one year low of $247.04 and a one year high of $698.67. The stock has a 50-day moving average price of $618.90 and a 200 day moving average price of $477.78. The company has a market capitalization of $48.80 billion, a P/E ratio of 165.37, a P/E/G ratio of 6.09 and a beta of 1.04.

Insider Activity

In other news, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $639.69, for a total transaction of $639,690.00. Following the completion of the transaction, the director now directly owns 24,259 shares in the company, valued at approximately $15,518,239.71. This represents a 3.96 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Julie A. Cullivan sold 1,261 shares of Axon Enterprise stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $682.06, for a total transaction of $860,077.66. Following the completion of the transaction, the director now directly owns 2,392 shares of the company’s stock, valued at $1,631,487.52. This trade represents a 34.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,545 shares of company stock valued at $30,721,337. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quent Capital LLC increased its position in Axon Enterprise by 1,875.0% during the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 75 shares during the period. Prestige Wealth Management Group LLC lifted its holdings in shares of Axon Enterprise by 115.8% in the third quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 44 shares in the last quarter. New Wave Wealth Advisors LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter valued at approximately $40,000. Brooklyn Investment Group bought a new stake in shares of Axon Enterprise during the 3rd quarter worth about $41,000. Finally, Y.D. More Investments Ltd acquired a new position in Axon Enterprise in the 4th quarter valued at $45,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.